Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.

NCT03891706 is registered in ClinicalTrials.gov with Guangzhou FineImmune Biotechnology Co., LTD. as lead sponsor.

NCT NCT03891706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03891706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.
Lead sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
January 8, 2019
Completion date
December 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor